10 Best Value Dividend Stocks to Buy According to Billionaires

4. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Billionaire Holders: 17

Forward P/E Ratio as of April 13: 7.50

Bristol-Myers Squibb Company (NYSE:BMY) is an American multinational pharmaceutical company, headquartered in New York. It mainly specializes in discovering and delivering innovative medicines. The company is building its growth strategy around a pipeline of cutting-edge therapies, with particular emphasis on its neuroscience drug, Cobenfy. Positive outcomes from ongoing trials could significantly impact the company’s long-term financial outlook.

With a steady dividend policy and targeted expansion efforts, Bristol-Myers Squibb Company (NYSE:BMY) remains attractive to income-seeking investors. In 2024, the approvals of Cobenfy and Breyanzi are expected to be major revenue drivers. During the fourth quarter, its Growth Portfolio brought in $6.4 billion—up 21% year over year—while total quarterly revenue rose 7.5% to $12.34 billion, supported by strong product demand. BMY offers a good entry point to investors in the current market with a forward P/E of 7.50. It is among the best value stocks to monitor according to billionaires.

On March 3, Bristol-Myers Squibb Company (NYSE:BMY) declared a quarterly dividend of $0.62 per share, which was in line with its previous dividend. Overall, the company has been growing its payouts for 16 consecutive years. In addition, it has never missed a dividend in 93 years, which makes it a reliable stock for income investors. The stock also offers an attractive yield of 4.89%, as of April 13.